Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Revenue	$ 0	$ 0
Operating expenses:
Research and development	17,729,000	19,487,000
General and administrative	8,786,000	10,017,000
Depreciation and amortization	126,000	127,000
Total operating expenses	26,641,000	29,631,000
Loss from operations	(26,641,000)	(29,631,000)
Other income:
Gain (loss) from change in fair value of warrant liability	6,125,000	(1,044,000)
Transaction costs allocated to warrant liabilities	(993,000)	(510,000)
Loss on issuance of warrant liabilities	(847,000)	0
Other income, net	43,000	48,000
Interest income, net	550,000	1,368,000
Net loss	$ (21,763,000)	$ (29,769,000)
Net loss per common share - basic and diluted (in dollars per share)	$ (6.32)	$ (15.07)
Weighted average common shares outstanding, basic and diluted (in shares)	3,442,997	1,975,610
Comprehensive loss:
Net loss	$ (21,763,000)	$ (29,769,000)
Other comprehensive loss:
Foreign currency translation	(32,000)	(21,000)
Comprehensive loss	$ (21,795,000)	$ (29,790,000)